RS Oncology

RS Oncology is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, with a mission to eradicate mesothelioma and other diseases globally through novel science and innovative business models. The company's lead program is currently focused on developing new therapies to modulate mitochondrial pathways, thereby driving oxidative stress-related diseases, including mesothelioma and other cancers.